Publicaciones en las que colabora con María Isabel Vera Mendoza (20)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

2022

  1. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

    Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 4, pp. 614-624

  2. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

    Biomedicines, Vol. 10, Núm. 3

  3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  4. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  5. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

2021

  1. Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

    Therapeutic Advances in Gastroenterology, Vol. 14

2020

  1. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents

    Journal of Gastroenterology and Hepatology (Australia), Vol. 35, Núm. 12, pp. 2080-2087

  2. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

    Scientific Reports, Vol. 10, Núm. 1

  3. Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: A nationwide study from the eneida registry

    Journal of Crohn's and Colitis, Vol. 14, Núm. 9, pp. 1290-1298

  4. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

2018

  1. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 8, pp. 839-851

2016

  1. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project

    Inflammatory Bowel Diseases, Vol. 22, Núm. 3, pp. 583-589

  2. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab

    Biochemical Pharmacology, Vol. 122, pp. 33-41

2013

  1. Health care costs of complex perianal fistula in Crohn's disease

    Digestive Diseases and Sciences, Vol. 58, Núm. 12, pp. 3400-3406

2011

  1. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

    Alimentary Pharmacology and Therapeutics, Vol. 33, Núm. 3, pp. 340-348

2009

  1. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

    Inflammatory Bowel Diseases, Vol. 15, Núm. 8, pp. 1190-1198

2008

  1. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis

    Alimentary Pharmacology and Therapeutics, Vol. 28, Núm. 5, pp. 623-628

  2. Open-label infliximab therapy in Crohn's disease: A long-term multicenter study of efficacy, safety and predictors of response

    Gastroenterologia y Hepatologia, Vol. 31, Núm. 7, pp. 421-426